Irish Medtech call for EU regulatory reform as leaders gather in Galway

(L:R) Stryker Senior Director Regulatory Affairs Mairead Twomey, Irish Medtech Director Eoghan Ó Faoláin, Senator Martin Conway Seanad Spokesperson on Health, Irish Medtech Senior Executive Dr Emer Sherry and Merit Medical Senior Director Regulatory Affairs Europe Mark Mullaney.

(L:R) Stryker Senior Director Regulatory Affairs Mairead Twomey, Irish Medtech Director Eoghan Ó Faoláin, Senator Martin Conway Seanad Spokesperson on Health, Irish Medtech Senior Executive Dr Emer Sherry and Merit Medical Senior Director Regulatory Affairs Europe Mark Mullaney.

Irish Medtech, the Ibec group that represents the medtech sector, is bringing together international leaders for the Global Access 2024 conference from October 23-24. The meeting will take place in the Galmont Hotel, Galway. Up to 250 people will be in attendance, and include policy makers, business leaders and regulators.

The event will feature a variety of speakers such as Senator Martin Conway Seanad Spokesperson on Health, Melissa Kann Vice President of Global RA/QA, Stryker and Bridget Clinton Senior Associate, Arthur Cox.

Irish Medtech Director Eoghan Ó Faoláin said, “Ireland is a global medtech leader, that delivers over €16 billion in exports to more than 100 countries demonstrating our extensive international reach. Industry must keep track of evolving international regulatory landscapes as well as seeking greater harmonisation and reliance among global regulatory systems. That is why we are hosting Global Access to ensure that Ireland remains competitive and innovative, by offering industry insights into the latest trends such as, international harmonization, sustainability, and clinical investigations.”

Irish Medtech Senior Executive Dr Emer Sherry added, “The European medtech sector is renowned for its constant innovation with over 15,985 patent applications filed with the Europe Patent Office in 2023. However, the costs, the complexity and lack of predictability of the EU regulations are hindering patient access to both current and new technologies. That is why we are calling for EU regulatory reform of the system to ensure it is efficient, innovation-friendly, and optimised for performance.”

 

Page generated in 0.3174 seconds.